Company intelligence / Profile preview

Boticinal

Davis, California, United States6sense.com ↗

Ownership: Private
Development stage: Commercial

Overview

Botanical Solution Inc. has developed a proprietary plant tissue culture platform to produce advanced botanical materials at scale. Its lead products are QS-21—a gold standard vaccine adjuvant used in several FDA-approved vaccines—and Quillibrium®, a biofungicide commercialized in Latin America and pending regulatory approval elsewhere. The company’s approach addresses supply chain bottlenecks and sustainability issues associated with traditional extraction from wild plants.

Therapeutic areas: OtherInfectious Diseases
Modalities: Small molecule
Industry: Biotech

Partnerships

Syngenta (distribution of Quillibrium/BotriStop)Croda International (distribution partner for ABMs/QS-21)

Beyond the preview

Go deeper on Boticinal.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Boticinal.

Explore the full profile